熱門資訊> 正文
薛定格与诺华合作获得监管机构批准
2025-01-13 20:33
- Health care technology company Schrödinger (NASDAQ:SDGR) announced on Monday the receipt of regulatory clearance for its research collaboration with Novartis (NVS) (OTCPK:NVSEF).
- The AI-driven drug discovery firm had inked a research and licensing agreement with Novartis in November.
- The upfront payment of $150M from Novartis is expected in the first quarter of 2025.
- Additionally, the company announced an expanded research collaboration with Otsuka Pharmaceutical.
- The company said the terms of the expanded collaboration are consistent with the previously announced agreement.
- Schrödinger is expected to report its Q4 results and provide 2025 financial guidance on Wednesday, February 26, after market close.
- SDGR shares were trading -1.50% pre-market at $19.00.
More on Schrödinger
- Schrödinger: Positive Signs Despite The Share Price Decline
- Schrödinger (SDGR) Q3 2024 Earnings Call Transcript
- Schrödinger, Inc. Continues To Be A Complicated Story
- Schrödinger gains on Novartis deal despite Q3 miss
- Schrödinger misses top-line and bottom-line estimates; updates FY24 outlook
推薦文章
港股周報丨三家外賣平臺被約談！「瘋狂星期六」或不再瘋狂；花旗呼籲增持中國互聯網、科技及消費板塊
美股機會日報 | 特朗普放大招！9萬億養老金即將殺入加密市場；美聯儲主席候選人支持7月降息
一周財經日曆 | 特斯拉、谷歌財報重磅來襲！維立志博將於下周五登陸港交所
一圖看懂 | 港股上半年IPO募資額登頂全球！中籤就賺一萬港幣的「大肉籤」你參與了嗎？
黃仁勛年內三度訪華！H20重返中國市場，釋放了什麼信號？
創新葯行情徹底爆發！維立志博-B打新半日孖展超購130倍，凍資近150億港元
新股申購 | 維立志博-B入場費3535.30港元！引入騰訊、易方達等基石投資者
7月財報預告丨迎關税考驗！特斯拉、臺積電放榜在即，美股能否守住漲勢？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
